首页> 美国卫生研究院文献>Clinical and Translational Science >Population Pharmacokinetic–Pharmacodynamic Modeling of Granulocyte Colony‐Stimulating Factor to Optimize Dosing and Timing for CD34 + Cell Harvesting
【2h】

Population Pharmacokinetic–Pharmacodynamic Modeling of Granulocyte Colony‐Stimulating Factor to Optimize Dosing and Timing for CD34 + Cell Harvesting

机译:群体药代动力学 - 粒细胞集落刺激因子的药效学建模以优化 CD34 + 细胞收获的剂量和时间

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Granulocyte colony‐stimulating factor (G‐CSF) mobilizes peripheral blood (PB) progenitor cells from bone marrow (BM) into circulation for PB stem cell transplantation (PBSCT). This study aimed to develop a population pharmacokinetic–pharmacodynamic (PK‐PD) model of filgrastim in healthy subjects to optimize PB CD34+ cell collection. Plasma filgrastim concentrations and CD34+ cell count data were obtained from a clinical study involving healthy Korean subjects. A total of 1378 plasma concentration measurements and 982 CD34+ cell count data collected from 53 subjects were used in the PK‐PD model. Filgrastim PKs were adequately described by a one‐compartment linear disposition model with an additional transit compartment for absorption. Log‐transformed body weight was the only significant covariate affecting the volume of distribution and clearance. CD34+ cell mobilization was best captured by a modified Friberg model, assuming continual entry of proliferating BM stem cells into PB via a single transit compartment. Simulation results suggested that the 5 μg/kg twice‐daily dosing regimen may yield higher CD34+ cell counts compared to the 10 μg/kg once‐daily regimen for achieving target CD34+ cell counts of 20/μL and 50/μL. We successfully developed a robust PK‐PD model of G‐CSF that optimizes the yield of CD34+ cells during allogeneic PBSCT. This model can guide the efficient determination of optimal G‐CSF dosing regimens and CD34+ cell harvesting strategies.
机译:粒细胞集落刺激因子 (G-CSF) 动员外周血 (PB) 祖细胞从骨髓 (BM) 进入循环进行 PB 干细胞移植 (PBSCT)。本研究旨在开发非格司亭在健康受试者中的群体药代动力学-药效学 (PK-PD) 模型,以优化 PB CD34+ 细胞收集。血浆非格司亭浓度和 CD34+ 细胞计数数据来自一项涉及韩国健康受试者的临床研究。PK-PD 模型共使用了从 53 名受试者收集的 1378 次血浆浓度测量和 982 次 CD34 + 细胞计数数据。非格司亭 PK 通过单室线性处置模型进行充分描述,并带有一个额外的转运室用于吸收。对数转换的体重是影响分布容积和清除率的唯一显着协变量。CD34 + 细胞动员最好通过改良的 Friberg 模型捕获,假设增殖的 BM 干细胞通过单个转运室持续进入 PB。模拟结果表明,与 10 μg/kg 每日一次方案相比,5 μg/kg 每日两次给药方案可能产生更高的 CD34+ 细胞计数,以达到 20/μL 和 50/μL 的目标 CD34+ 细胞计数。我们成功开发了一种稳健的 G-CSF PK-PD 模型,该模型可在同种异体 PBSCT 期间优化 CD34 + 细胞的产量。该模型可以指导有效确定最佳 G-CSF 给药方案和 CD34 + 细胞收获策略。

著录项

代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号